In April 2009, a novel swine-origin influenza A (H1N1) virus was identified in patients from Mexico and North America. The new virus spread around the world and the World Health Organization (WHO) declared a pandemic level of 6[@b1]. Since then, several publications presenting clinical and epidemiological characteristics and discussing risk factors associated to the H1N1 patients in Mexico have been published[@b2][@b3][@b4]. Mexico documented the largest number of confirmed cases during the first and subsequent outbreaks as documented in literature[@b5]. In this work we first documented major potentially-toxic elements concentration in 40 cases of pneumonia and confirmed viral infection among hospitalized patients at the National Institute for Respiratory Diseases (INER) in Mexico. Key nutritional essential elements have been also documented in this analysis. Two control groups, negative for the pandemic strain, were selected among Mexico City population at INER and the National Institute of Nutrition (INCMNSZ) and compared versus toxicology and essential element profiles of AH1N1 patients, a group of young Mexicans, overall in good health, that presented acute respiratory illness through AH1N1 viral infection during pandemic year[@b6]. We discussed and correlated these levels with the occurrence and severity of the viral infection disease.

Results
=======

Participants of the study
-------------------------

Participants are divided in two main groups: Cases and Controls (I and II). The first group is referred to 40 AH1N1 cases (pneumonia hospitalized cases with confirmed viral infection through RT-PCR assay). Sample collection for this group was done from October 1^st^ to December 31^st^ 2009 and from January 15^th^ to April 15^th^ 2010 during pandemic year-period[@b6]. The second group is subdivided as Controls I and II. The first group (Controls I) is referred to 30 pneumonia cases negative for the pandemic strain through RT-PCR assay. The second group is referred to 64 persons admitted, treated for ILI (Influenza like Illness) symptoms also negative for the specific virus strain (through RT-PCR assay). Criteria for selection as a "control case" was being a relative living with the patient at the time of the disease, exposed to the virus through direct contact with him/her for at least three days before his/her hospitalization. Controlled cases were selected for the present study accordingly to the period of our key AH1N1 samples were collected, i.e., from October 2009 throughout April 2010. Inclusionary and exclusionary criteria for selection of the control groups are summarized in [Table 1](#t1){ref-type="table"}.

Admission features of AH1N1 cases and controls
----------------------------------------------

*Cases.* The start time of symptoms and admission to hospital ranged from 7--12 days (mean: 9 days). All patients had fever, temperatures higher than 38.5°C, cough, respiratory distress and other clinical features described for Mexico City cases[@b2]. Sample for the present study was taken between the time of admission and *positive* results on the virus strain (AH1N1) through RT-PCR assay (2 days) before receiving any medication for the illness. At the time of admission thirty-six (90%) of study patients had increased lactase dehydrogenase (DHL) levels ranged from 511--1585 IU per liter. Twenty patients (50%) presented lymphocytopenia (low-normal lymphocytes account \<1,000 per cubic millimeter). Three patients presented elevated creatinine levels (2.32--3.45 mg per deciliter). Fifteen cases (38%) presented lower than referenced hemoglobin values (Hb ≤ 12 grams per deciliter). Eight cases were off threshold than referenced values in hematocrit (36%--52%). All selected cases with unknown history of occupationally toxic-metals exposure. [Table 2](#t2){ref-type="table"} presents characteristics of AH1N1 cases selected for the study.

### Controls I and II

The start time of symptoms and admission/diagnosis in the hospital was between 5--7 and 3--5 days for Controls I and II, respectively. Controlled cases presented identical symptoms to those featured for the key cases, negative for the pandemic strain, all recovered from illness. They presented unknown history of occupationally toxic-metals exposure and went through blood tests as part of the research protocol approved by the National Council of Science and Technology of Mexico (CONACyT-Reference 126657-2009-02) during pandemic year. Sample for control groups was taken between the time of admission and *negative* results on the RT-PCR assay (2 days) before receiving any medication for the illness. Main characteristics of Controls I and II are summarized and compared to AH1N1 cases in [Table 2](#t2){ref-type="table"}. Details of both groups are described in Methods Section.

Critical care cases: survivals and non-survival AH1N1 patients
--------------------------------------------------------------

Ten of our AH1N1 cases received tracheal intubation; seven of these not survived. There were a total of 8 non-survivals AH1N1 patients documented in this research. All of them corresponded to samples taken in 2009 (1^st^ October to 31^st^ December). None of the non-survival patients received 2009 AH1N1 or seasonal influenza or pneumococcal vaccination before illness and hospitalization. All of these cases had obesity in some extent (5 cases: type I; 1 case: type II; 2 cases: morbid). Only three of them had a history of current smoking, suspended at the time of presenting symptoms. Mean age of non-survival patients (8/40) of the study was 45.33 years.

Multi-element determination in whole blood of AH1N1 cases and controls
----------------------------------------------------------------------

28--31 metals and metalloids were accurately reproducible through evaluation of certified and referenced standards described in Methods Section. Results of the present study are focused on whole blood concentration levels of the following elements: lead, mercury, chromium, cadmium, arsenic and selenium, zinc, copper, calcium and sodium.

(a) Potentially-toxic metals profile for cases and controls analysed
--------------------------------------------------------------------

[Table 3](#t3){ref-type="table"} describes statistic parameters for concentration levels of lead, mercury, cadmium, arsenic and chromium in whole blood of cases and controls analysed. [Table 4](#t4){ref-type="table"} presents statistical analysis results for lead and mercury heavy-metals. Details of statistics approaches applied to evaluate significant differences between cases and controls are depicted in Methods section.

### Lead (Pb)

Blood lead levels ranged from 43.77 to 366.18 ppb for AH1N1 cases and from 2.04 to 112.7--191.6 ppb for controls. Mean blood lead levels for cases were greater than literature[@b7] values (62.8 ppb) 75% of the time (30/40 cases) while for Controls I and II this was registered 27% (8/30 controls) and 22% (14/64 controls) of the time, respectively. Mean blood lead levels for AH1N1 patients were two and almost three times larger than Controls I and II, respectively while median values were almost twice (1.9) larger versus Controls I and more than 3 times (3.3) than Controls II. Two cases (of the 40 AH1N1) had blood lead levels greater than the threshold (≤250 ppb for adults) delimited by Mexican Norm[@b8], while ten (25%) of the total cases had levels greater than recommended values by the Center for Diseases Control (≤150 ppb in young adults). Nonetheless, seven of these ten cases recovered from the illness and survived. Statistical analysis ([Table 4](#t4){ref-type="table"}) showed blood lead levels of AH1N1 patients versus Controls I and II met highly statistical significance while lead concentrations between subgroups of Controls (I versus II) did not.

### Mercury (Hg)

Mean blood mercury levels for cases (AH1N1) and Controls (I and I) were slightly higher than threshold referenced[@b7][@b9][@b10] values (mean 1.1 μg/dL). As shown in [Table 4](#t4){ref-type="table"}, statistical analysis between blood mercury levels of pneumonia --infected AH1N1 patients versus Controls II (ILI cases) met highly statistical significance while between Controls I (pneumonia cases) and controls II did not. Probable reasons for Hg blood levels found among population living in Mexico City during pandemic influenza might be the content of mercury in airborne particulate matter recently reported in literature[@b11]. Mercury belongs to one of the most harmful xenobiotic with severe implications (e.g., kidney impairment) although chronic low-dose exposure remains still not well understood[@b9].

### Chromium (Cr)

Chromium blood levels for AH1N1 patients ranged from 0.278 to 8.94 μg/dL; mean of 4.604 ± 1.94 SD μg/dL, greater than literature[@b12] reported values. Cr (as well as Cd and As) determinations in samples of control group (I) were not achieved for this pandemic study. In spite of this, samples of cases and controls II analysed showed mean and median blood levels of AH1N1 patients were substantially higher, almost four (3.9) and five (4.8) times, than concentration levels found for this elements in the control group --II. Statistical analysis is not performed for Chromium as more than 50% of the values are within the lower detection limit (LDL) of the analytical technique, as detailed in [Table 3](#t3){ref-type="table"}.

### Cadmium (Cd)

Blood cadmium levels in AH1N1 patients ranged from 1 to 21.79 ppb. Overall mean 10.7 ± 2.63 SD ppb, remarkably larger than referenced[@b7][@b13] values (0.4--4.0 ppb). Cadmium high levels have been related to an increased risk to organ failure. Exposure to Cd can also result in damage to a variety of organ systems[@b14][@b15]. Cadmium, at levels greater than referenced values, represents a serious threat particularly to the vascular endothelium, the immune system, the nervous system, and even the local chemical/metabolic environment of individual organs[@b16][@b17][@b18]. Nevertheless, only two AH1N1 cases having highest Cd concentrations did not recover from illness. As seen in [Table 3](#t3){ref-type="table"}, more than 50% of the Cd concentrations of both cases and controls (II) were detected within the LDL resulting in an important limitation to evaluate statistical significance between subgroups.

### Arsenic (As)

Blood arsenic levels for AH1N1 patients ranged from 1 to 44 ppb; mean of 8.62 ± 12.27 SD ppb, remarkably greater than literature[@b7] values (range: 2.6--17.8 ppb; mean: 5.0 ppb). Indeed, seven of our eleven AH1N1 cases having the highest As concentrations (range: 11--36 ppb) did not recover from illness. Nevertheless, as seen in [Table 4](#t4){ref-type="table"}, more than 50% of the As concentrations of both cases and controls (II) were detected within the LDL resulting in an important limitation to evaluate statistical significance between subgroups.

(b) Essential elements profile for cases and controls analysed
--------------------------------------------------------------

[Table 5](#t5){ref-type="table"} describes statistic parameters for concentration levels of selenium, zinc, calcium, sodium and cooper in whole blood of analyses cases and controls I and II. [Table 6](#t6){ref-type="table"} presents statistical analysis results for selenium (Mann-Whitney/Bonferroni correction) and the rest of essential elements (Mann-Whitney U Tests). Statistics analysis approaches are detailed in Methods section.

### Selenium (Se)

Mean blood Se levels for AH1N1 was 10.62 μg/dL, versus controls I and II concentrations of 13.67 and 15.46 μg/dL, respectively; within reported[@b7][@b13][@b19] values for young population (mean range: 11.0 to 15.0 μg/dL). Overall blood selenium values in key AH1N1 cases tended to decrease versus controls I and II. This is in agreement with results showed in [Table 6](#t6){ref-type="table"} where blood selenium levels of AH1N1 patients were statistically significantly lower when compared to both Controls I and II. It is also noted that selenium blood levels also reached statistical significance for Controls I (pneumonia) when compared to controls II (ILI).

### Survival and non-survival AH1N1 cases

Cases with selenium concentrations greater than 12.5 μg/dL-level, suggested as the optimal cut-off for glutathione peroxidase activity[@b20] recovered from illness in fewer days (5--7 days) than the average time (10--12 days for pneumonia; 15--21 days for pneumonia --AH1N1 infected ones) registered for cases analysed during pandemic year at INER. Seven (7/8) non-survival cases registered selenium levels lower than the optimal cut-off abovementioned. Four of critical patients presenting severe renal failure reached the lowest Se values: 8.23, 7.81, 7.07, 6.21 μg/dL accordingly with progression (three different samples collected during 15--21 days of hospitalized period) and severity of the illness and finally did not recover from it. Levels of selenium of cases abovementioned were similar to that reported[@b20] for pregnant women who tend to decrease when increasing time of gestation, 1^st^ trimester: 7.55--8.5 μg/dL; 2^nd^: 7.2--8.1 μg/dL; 3^rd^: 6.99--7.75 μg/dL[@b21]. Pregnancy has been set as a determinant risk factor (increasing fatal evolution with time of gestation) for reported cases[@b3] during pandemic influenza although none of the cases under discussion in our study corresponded to this condition. The concentration of selenium in whole blood varies widely between geographic areas depending on its content in soil, dietary Se intake, retention and interaction with other minerals in the body organism[@b22]. Despite the fact that Mexico City is not particularly considered as low-selenium area, a supplement of this essential metal might be considered on the recovery of pneumonia patients with particular emphasis on those infected by AH1N1 strain, as analysed in this research.

### Zinc (Zn)

Mean blood zinc levels for cases corresponded to 669.48 ± 260.01 SD μg/dL, very similar to those obtained for controls II (662.469 ± 271.8 SD μg/dL). Zinc (as well as calcium, sodium and copper) determinations in samples of control group (I) were not achieved for this pandemic study. As shown in [Table 5](#t5){ref-type="table"}, mean and median values of both cases and controls are in the inferior value limit of literature[@b13][@b10] (range: 600--990 μg/dL), and significantly lower than values reported recently for young Mexican population[@b23] (930--1340 μg/dL). No statistically significant differences were observed when compared Zn blood levels of AH1N1 cases versus controls, as presented in [Table 6](#t6){ref-type="table"}. Nevertheless, 62% of lowest Zn values (282--586 μg/dL) registered for key cases did show a correlation (R = 0.978) with corresponding higher lead levels (≥15 μg/dL). Adequate Zn concentrations have been suggested to be effective as a preventive way for pneumonia infection[@b24] nevertheless whether nutritional deficiencies affects bronchial epithelial cells and modify susceptibility of viral influenza remains not well understood.

Zinc concentrations in blood are a key feature in the analysis of Zn to Cu ratios of cases and controls presented below.

### Survival and non-survival patients

There were no substantial differences in blood Zn levels between survivals and non-survivals for AH1N1cases analysed here.

### Calcium (Ca)

Blood calcium levels for cases ranged from 1.8 to 4.82 mg/dL; mean value of 3.98 mg/dL. For controls II ranged concentrations ranged from 1.77--4.94 mg/dL; mean value of 3.90 mg/dL, both below literature values (5.75 to 10 mg/dL). Calcium concentrations were not achieved for samples of controls-I as aforementioned. No statistically significant differences were observed when compared calcium blood levels of cases versus controls II, as shown in [Table 6](#t6){ref-type="table"}. Nevertheless, lesser calcium values (30% lower than mean values) corresponded 60% of the time with higher lead values (≥14--15 μg/dL) for AH1N1 cases under study.

### Survival and non-survival patients

There were no substantial differences in blood Ca levels between survivals and non-survivals for AH1N1cases analysed here.

### Sodium (Na)

Blood sodium levels for key cases ranged from 188.04 to 316.04 mg/dL; mean value 271.95 mg/dL. Blood sodium levels for controls --II ranged from 260--317 mg/dL; mean value of 286.72 mg/dL; slightly below literature values (300--320 mg/dL). Sodium concentrations were not achieved for samples of controls-I as aforementioned. No statistically significant differences were observed when compared sodium blood levels of cases versus controls II, as shown in [Table 6](#t6){ref-type="table"}.

### Survival and non-survival patients

There were no substantial differences in blood Na levels between survivals and non-survivals for AH1N1cases analysed here.

### Copper (Cu)

Blood copper levels for AH1N1 patients ranged from 64.34 to 163.74 μg/dL and 102 to 208 μg/dL for controls II. Mean values of 111.55 and 127 μg/dL for cases and controls -II, respectively, both within literature (80--140 μg/dL). Copper concentrations were not achieved for samples of controls -I as aforementioned. Significance was achieved for Cu concentrations levels between AH1N1 cases and controls --II as shown in [Table 6](#t6){ref-type="table"}.

A metabolic imbalance is observed when deficiency of the essential element resulted in higher ratios of zinc to copper for AH1N1 influenza cases under study (6.07) versus their controls (5.52). It is also noted that Cu blood levels in AH1N1 patients tended to decrease (and ratios of zinc to copper tended to increase) accordingly with obesity, in agreement with previous studies[@b25]. For AH1N1 cases analysed in this research this was particularly observed for category III (morbid).

### Survival and non-survival patients

Differences in blood copper levels between survivals and non-survivals AH1N1 cases were observed when a pre-condition (particularly, obesity III) occurred. Number of cases to evaluate significance between copper levels was a limitation to perform statistical analysis between these two subgroups.

Discussion
==========

We have showed that whole blood (WB) profile of potentially-toxic heavy metals in pneumonia -AH1N1 infected patients was statistically significant (Pb, Hg) and remarkably (Cd, Cr, As) different when compared with WB levels of pneumonia and ILI controls, both negative for the pandemic strain. Higher WB lead concentrations (≥14--15 μg/dL) for cases under study were related (in 38% of the cases) to a lower than referenced values of hemoglobin; lesser concentrations of Ca^2+^ and Zn^2+^ (60--62% of the time) were registered for aforementioned concentrations as well. Substitution of essential elements by lead has been widely mentioned in literature though underlying mechanisms have not been fully elucidated[@b26]. Spite the fact that key cases and controls were selected accordingly to specific guidelines of the research protocol regarding "no exposure to a specific environmental source of toxicity related to the metals and metalloids considered in the study", concentration levels of some potentially-toxic metals (*e.g.* Pb) found in this study might be, in part, caused by an unknown source determined by environmental conditions of Mexico City inhabitant\'s resident such as legacy of past domestic uses (leaded paints or ceramics) as well as environmental exposure to dust and soil remissions containing heavy-metals[@b27]. Environmental exposure to lead through airborne particulate matter might be considered with reserves as leaded gasoline was phase-out from Mexico by federal and local stricter regulations on this matter since 1997[@b28]. On the other hand, potentially-toxic blood levels of at least three of the five heavy-metals studied (Pb, Cd, Cr) were remarkably higher in AH1N1 --infected patients segregated by smoking factor. Indeed lead and cadmium high levels have been related unequivocally to the condition of smoking[@b15] and increased organ failure[@b14][@b15]. Nevertheless, statistical analysis was not conclusive on this matter (inhomogeneity of different subgroups), particularly in the context of severity of the illness (survival or non-survival patients), at least for cases under study. Along with significant concentrations of potentially-toxic elements, deficiency of some essential metals (Se, Cu) characterized AH1N1 viral-infection cases in Mexico City. WB levels of selenium in AH1N1 patients remained statistically significantly (*p*\<0.001) lower (mean: 10.42 μg/dL) than controls I and II (means 13.67; 15.19 μg/dL, respectively). It is noted highly statistically significant decrement of selenium from controls II (influenza like illness) through controls I (pneumonia) and finally in pneumonia -AH1N1 infected patients, the latter registering the lowest values of the essential element. Selenium values for critical (ICU) patients who survived from those who did not, capture our attention. Results showed that all AH1N1 patients having blood Se levels greater than the recommended level for an optimal cut-off to activate glutathione peroxidase (12.5 μg/dL) recovered from the illness in a shorter time and survived. Nevertheless the effect of selenium status on responses to viral infection is not fully understood, selenium depletion has been shown in a cell culture model to affect influenza virus-induced cytokine production in bronchial epithelial cells[@b29]. With regards to renal failure (non-survival cases), it should be noted that this condition further decreases Se levels and glutathione peroxidases in blood[@b30]. Based on clinical-lab features of ICU patients who survived from those who did not, evaluation of key nutrients, such as selenium, is currently under evaluation in the recovery of pneumonia -viral -infected patients at the National Institute for Respiratory Diseases. Finally, increased Zn/Cu ratios were observed in AH1N1 patients versus controls not infected with the pandemic strain. Furthermore, Zn/Cu ratios were remarkably high for AH1N1 cases where obesity (category II-III) was a pre-existing condition. This enforces results discussed by the WHO consultation on clinical aspects of pandemic influenza[@b3].

Methods
=======

Study participants
------------------

### AH1N1 patients

The pandemic influenza study was conducted at INER as part of a national public health investigation during the collection of AH1N1 samples and review of clinical data (2^nd^ semester 2009-1^st^ semester of 2010). Selection of the key AH1N1 cases was done accordingly to standards and specifications of the research protocol approved by the National Council of Science and Technology in Mexico (CONACyT-Reference 126657) in 2009. The pandemic influenza study was also approved by the Committee of Science and Bioethical of the National Institute of Respiratory Diseases in the same year. All patients selected had pneumonia and positive result on reverse-transcriptase-polymerase-chain-reaction (RT-PCR) testing for influenza A (H1N1) according to guidelines from the U.S. Center for Control Diseases and Prevention (CDC) published during pandemic influenza[@b31]. All participants received Institutional informed written consent also approved by Institutional Committee of Bioethics and Science at INER, before the sample collection and laboratory tests.

### Control subjects

Two groups of controls were selected for purposes of our study. Controls -I corresponded to thirty (30) subjects admitted and diagnosed with pneumonia but negative for the pandemic strain. Controls --II corresponded to 64 subjects directly exposed to the AH1N1 virus in Mexico City diagnosed as influenza like illness (ILI) and also negative for the pandemic strain. Controls were persons in contact with an AH1N1 patient and were selected at both National Institutes for Respiratory Diseases (INER) and Medical Sciences and Nutrition (INCMNSZ) accordingly to guidelines detailed in the research protocol aforementioned. Sample collection of controls initiated during first outbreak and extended throughout WHO pandemic year. They were selected according to the age range of influenza patients (20--55 years), having unknown history of occupational toxic exposure, and with any influenza (AH1N1 or seasonal) or pneumococcal vaccines previously to blood sample was taken. Criteria for selection of the control during pandemic period was being one of the closest AH1N1 patient\'s relatives (not by blood), exposed to the virus through direct contact with him/her for at least three (3) days before patient\'s hospitalization. All participants received medical consultation, blood (biometry and toxicology) tests accordingly to the CONACyT research protocol and were selected having unknown history of pre-existing health conditions. Controlled cases received Institutional informed written consent also approved by the Committee of Bioethics and Science at INER, before the sample collection and laboratory tests. Both INER and INCMNSZ are National Institutes and public hospitals that serve a low-moderate income population mainly from Mexico City and its Metropolitan Area. For inclusionary and exclusionary criteria of selection as a "control" for pandemic influenza research protocol, reader is referred to [Table 1](#t1){ref-type="table"}.

### Clinical-lab data

Clinical-medical charts of the 40 patients hospitalized for pneumonia at INER were reviewed. Real Time-Polymerase Chain Reaction (RT-PPCR) of all patients was positive for AH1N1 at admission though nasopharyngeal-swab sample or after tracheal intubation for Intensive Care Unit (ICU) cases. All procedures for RT-PCR assay were followed according guidelines provided by the U.S. CDC in 2009. Age, gender, history of smoking, diabetes mellitus or other pathologies, body mass index (BMI) as well as laboratory clinical levels of serum lactase dehydrogenase (DHL), leukocyte counts, creatinine, hemoglobin and hematocrit levels at admission were compiled in the clinical-lab database for the study.

### Blood sample collection

Trained medical and research staff performed all sample collection at the National Institutes (INER and INCMNSZ) in Mexico City, Mexico. Original plus replicate whole-blood samples of 3--5 ml were collected in metal-free tubes for multi-elemental trace element analyses. All whole-blood collection and processing materials were acid cleaned, according to Mexican Norms[@b8]. All reagents were ultra-high purity or ultrapure analytical grade. Selected samples for the protocol were frozen at -20°C at the INCMNSZ until chemical analyses, according to sample collection guidelines for trace elements in blood[@b32].

### Trace elements quantification

28--31 metal and metalloid determination were quantified from 60 acid-digested whole blood samples (AH1N1 patients\' samples plus blanks and calibration standards) through an Inductively-Coupled Plasma Mass Spectrometer (ICP-MS; Agilent Technologies, U.S.) and an Atomic Absorption Spectrometer (AAS; Perkin Elmer, U.S.) at Laboratory of Instituto de Ciencias del Mar y Limnología from the National Autonomous University of Mexico (UNAM). Elements determined through ICP-MS were Li, Mg, Al, K, Ti, V, Cr, Mn, Fe, Co, Ni, Cu, Zn, Ge, As, Se, Sr, Y, Mo, Ag, In, Sn, Sb, Ba, Tl, Pb, Hg and Bi. Lead and zinc quantifications were double-verified by AAS-- graphite furnace; technique that was also applied for cadmium determination. Mercury was determined by AAS- hydride generation. Finally, calcium and sodium measurements in whole blood were performed by AAS-flame. The three variants (flame, hydride generation and graphite furnace) of the AAS technique are literature recommended techniques for quantification of metals and metalloids of interest. The CONACyT research protocol was also subject to external quality control on the elemental analysis to verify ICP-MS and AAS determinations of the core (blood) samples of AH1N1 patients through an Inductively Coupled Plasma- Collision Cell- Mass Spectrometer (ICP-CC-MS) at the Instituto de Geología from the Autonomous University of San Luis Potosí (UASLP), San Luis Potosí, Mexico. Details of the analytical technique are depicted elsewhere[@b33]. As part of quality control program and the inter-comparison of internal and external laboratories we applied same certified referenced materials from the International Atomic Energy Agency (IAEA-A-13 freeze dried animal blood) and High Purity (CRM-Bovine Liver) to evaluate accuracy and reproducibility of the analytical methods aforementioned. ICP-MS determinations reported here had an adequate linearity, accuracy and precision during the quantification study. Briefly, the method yields a measurement precision of ≤0.5%RSD for lead (reference potentially-toxic element) concentrations of \<0.003 μg/ml. Trace-elements from control samples were also double-verified by ICP-CC-MS following the same ICP-MS methodology and certified standards. The analytical detection limit determined was 0.1 μg/dL for ICP-CC-MS and 1--2 μg/dL for AAS. Metal and metalloid concentrations are reported in micrograms per deciliter (μg/dL) or micrograms per liter (ppb), unless otherwise indicated.

### Statistical Analysis

Non-parametric analysis was applied to evaluate significant differences on concentrations of potentially-toxic elements and essential elements in whole blood of AH1N1 patients versus their controls. This variant was chosen as at least one assumption, *e.g.* independence and normality or homogeneity of variances was not adequate to perform one-way ANOVA analysis. Kruskal-Wallis test was applied to evaluate significant differences concentrations of potentially-toxic elements lead and mercury and essential element selenium in whole blood of AH1N1 patients versus their controls I and II. Mann-Whitney Post Hoc test was performed for pairwise multiple comparisons with a Bonferroni correction to achieve that no more than a five percent of chance of making a type-1 error for any of the hypotheses being tested was present. For the rest of essential elements: zinc, copper, calcium and sodium Mann-Whitney U test was applied to evaluate if significant differences were observed between concentration levels in whole blood of AH1N1 patients versus their respective controls (II). Data reported in the present study is expressed as mean ± SD (standard deviation), median and IQR (Inter-quartile range). Significance was set as *p\<0.05*; highly statistical significance was considered as *p\<0.001.*
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###### Inclusionary and exclusionary criteria for selection of Controls --I and II during pandemic study

  -------------------------------------------------------------------------------------------------
  **Inclusionary criteria**
  1\) 20-55 years old; living in Mexico City metropolitan area
  2\) Relative (not by blood)
  3\) Admitted and treated for different reasons (pneumonia: Controls- I)
  4\) Admitted and treated for different reasons (ILI symptoms; Controls- II)
  5\) Negative Real Time-Polymerase Chain Reaction assay on pandemic (AH1N1) strain
  6\) Range of Hemoglobin: 12.0 g/100 mL-16.0 g/100 mL
  7\) Range of Hematocrit: 38--48%
  8\) Body weight: indistinct; overweight (BMI \> 25) preferred
  **Exclusionary criteria**
  1\) Pregnancy or breastfeeding
  2\) H1N1 or seasonal influenza or pneumococcal vaccinations received[a](#t1-fn1){ref-type="fn"}
  3\) VIH or auto-immune diseases
  4\) Hepatitis (any kind)
  5\) Allergies (any kind)
  6\) Medical treatment (any kind)
  7\) Use of toxicology substances (any kind)
  -------------------------------------------------------------------------------------------------

^a^One control --I received pneumococcal vaccine before sample was taken.

###### Characteristics of AH1N1 Cases and Control study groups (Control I and II)

  Variable                                                            AH1N1         Controls--I     Controls-II
  ------------------------------------------------------------- ----------------- --------------- ---------------
  Female sex-number/total No. (%)                                  14/40 (35%)      12/30 (40%)    21/64 (32.8%)
  Age (years)                                                                                             
      Mean (±SD)                                                  41.34 ± 12.6      44.2 ± 7.97     32.46±10.64
      Range                                                          19--55           20--55          20--55
      Median/IQR                                                      44/26            46/12           31/16
  Segregated (%)                                                                                          
      19--30 yr.                                                   15 (37.5%)         4 (13%)       35 (54.7%)
      31--45 yr.                                                    10 (25%)          8 (27%)       21 (32.8%)
      46--55 yr.                                                   15 (37.5%)        18 (60%)        8 (12.5%)
  Smokers[1](#t2-fn1){ref-type="fn"} -number/total number (%)       23 (57%)         11 (37%)        23 (36%)
  Vaccinations                                                                                            
  Influenza AH1N1/pneumococcal                                      0/40 (0%)        0/30(0%)       1/64 (1.5%)
  Body Mass Index-number/total No. (%)                                                                    
      \< 25                                                        14/40 (35%)                            
      25--29.9                                                    13/40 (32.5%)    25--30 (100%)   25--30 (100%)
      30--39.9 (II)                                               11/40 (27.5%)                           
      Morbid (III)                                                 02/40 (5%)                             
  Laboratory findings-median (range)                                                                      
      Lactase dehydrogenase-U/liter                              884 (511-1585)         410             362
      Lymphocyte count -- per mm^3^                              801 (350--2600)   \>1000/mm^3^    \>1000/mm^3^
      Hemoglobin - g dL^-1^                                           13.8             13.9            14.4
      Hematocrit - %                                                  39.07            39.4            42.09
  Pre-existing conditions-number/total No. (%)                                                            
      Diabetes Mellitus (type 2)                                    2/40 (5%)          None            None
      Asthma                                                       1/40 (2.5%)         1/30            None
      CPOD                                                         1/40 (2.5%)         None            None
  Abnormal laboratory findings-number/total No. (%)                                                       
  Only AH1N1 cases                                                                                        
      Lactase dehydrogenase \> 350 U/liter                        37/40 (92.5%)                           
      Lymphocyte count \<1000 per mm^3^                            20/40 (50%)                            
      Hemoglobin ≤ 12 g dL^−1^                                     15/40 (38%)                            
      Hematocrit (38%--52%)                                        8/40 (20%)                             

^1^History of current smoking is referred to smoking less than 10 cigarettes a day which is known as light-to-moderate smoking.

###### Potentially-Toxic Elements Profile: Descriptive Statistics

  Element                       N     Min    Mean     SD                 Median                            IQR                  Max
  ------------ --------------- ---- ------- ------- ------- -------------------------------- -------------------------------- --------
  Pb (ppb)          Cases       40   43.77   115.4   67.94                96.8                            30.39                366.8
                 Controls-I     30   10.96   52.54   28.67                50.6                            38.08                112.71
                 Controls-II    64   0.35    42.70   38.20                28.8                            41.84                191.57
  Hg (μg/dL)        Cases       40   0.885   1.386   0.250               1.392                            0.344                2.175
                 Controls-I     19   1.030   1.242   0.107               1.240                            0.125                1.397
                 Controls-II    42   0.809   1.156   0.293               1.185                            0.297                2.018
  Cr (μg/dL)        Cases       40   0.278   4.604   1.94                 4.86                             2.43                8.942
                 Controls-II    44   0.700   1.18    0.65                 0.99                0.0[2](#t3-fn2){ref-type="fn"}   4.113
  Cd (ppb)          Cases       40    1.0    10.87   2.63                 1.0                 0.0[2](#t3-fn2){ref-type="fn"}   21.79
                 Controls-II    64    1.0     1.0    0.00    1.0[1](#t3-fn1){ref-type="fn"}   0.0[2](#t3-fn2){ref-type="fn"}    1.0
  As (ppb)          Cases       40    1.0    8.62    12.3                 1.0                               11                   44
                Controls --II   64    1.0     1.0    0.00    1.0[1](#t3-fn1){ref-type="fn"}   0.0[2](#t3-fn2){ref-type="fn"}    1.0

^1^Lower detection limit (1 ppb = 0.1 μg/dL) of ICP-MS-collision cell.

^2^\>50% of the values are detected within LDL.

###### Potentially-Toxic Elements: Statistical analysis

  a\) Kruskal Wallis test.                                                      
  -------------------------- ----- -------------------------- ----------------- ---------
  Element                      N    Kruskal Wallis Statistic   Degrees Freedom   p-value
  Pb                          135            47.382                   2           0.000
  Hg                          101            22.864                   2           0.000

  b\) Multiple bivariate comparisons. Post Hoc Bonferroni correction.                                               
  --------------------------------------------------------------------- --------------------- ----------- --------- ----------------------------------------------------------
  Element                                                                  Category Group      Statistic   p-value   p value Bonferroni correction[1](#t4-fn1){ref-type="fn"}
  Pb (ppb)                                                               Cases vs. Control I    39.257      0.000                             0.000
  Cases vs. Control II                                                         53.472            0.000      0.000                                
  C -I vs. C -II                                                               14.215            0.100      0.300                                
  Hg (μg/dL)                                                             Cases vs. Control I    15.329      0.060                             0.181
  Cases vs. Control II                                                         30.940            0.000      0.000                                
  C -I vs. C -II                                                               15.612            0.054      0.162                                
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1Corresponds to 0.05 significance level.

###### Essential Elements Profile: Descriptive Statistics

  Element                     N     Min      Mean      SD     Median    IQR       Max
  ------------ ------------- ---- -------- -------- -------- -------- -------- ---------
  Se (μg/dL)       Cases      40    6.22    10.62     2.81     9.68     3.22     18.00
                Controls I    19   11.69    13.67     1.14    13.93     1.92     15.94
                Controls II   64   11.13    15.46     1.81    15.13     2.17     21.86
  Zn (μg/dL)       Cases      40   282.26   669.48   260.01   597.52   320.01   1285.40
                Controls II   65   432.02   662.47   271.80   582.32   108.01   2148.10
  Ca (mg/dL)       Cases      40    1.80     3.99     0.57     4.07     0.57     4.82
                Controls II   39    1.77     3.90     1.22     4.29     0.50     4.94
  Na (mg/dl)       Cases      40   188.04   271.96   23.62    274.89   15.75    316.04
                Controls II   11   259.56   286.72   19.55    287.62   29.16    317.27
  Cu (μg/dL)       Cases      40   64.34    111.55   23.05    108.29   27.18    163.74
                Controls II   24   102.55   126.63   28.61    112.78   26.25    207.99

###### Essential Elements: Statistical Analysis

  a\) Kruskal Wallis test.                                                      
  -------------------------- ----- -------------------------- ----------------- ---------
  Element                      N    Kruskal Wallis Statistic   Degrees Freedom   p-value
  Se                          124            59.424                   2           0.000

  b\) Multiple bivariate comparisons. Post Hoc Bonferroni correction.                                                                          
  --------------------------------------------------------------------- --------------------- ------------- ---------------------------------- --------------------------------------------------
  Element                                                                  Category Group      Mann Whiney               p-value                Bonferroni correction[1](#t6-fn1){ref-type="fn"}
  Se (μg/dL)                                                             Cases vs. Control I     −28.220                  0.003                         0.008[1](#t6-fn1){ref-type="fn"}
  Cases vs. Control II                                                         26.940             0.007      0.021[1](#t6-fn1){ref-type="fn"}                           
  C -I vs. C --II                                                              55.160             0.000      0.000[1](#t6-fn1){ref-type="fn"}                           

  -------------------------- ---------------------- --------- ------------------- ------------ ---------
  c\) Mann-Whitney U test.                                                                     
  Element                                            p-value   Median difference   CI (95%)\*  
  Zn(μg/dL)                   Cases vs. Control II    0.853          6.283          −56.858     81.176
  Ca (mg/dL)                  Cases vs. Control II    0.090          0.027           −0.386     −0.176
  Na (mg/dl)                  Cases vs. Control II    0.074         −12.904         −26.557      1.699
  Cu (μg/dL)                  Cases vs. Control II    0.023         −11.989         −22.335     −11.989
  -------------------------- ---------------------- --------- ------------------- ------------ ---------
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^1^Corresponds to 0.05 significance level.\* Hodges-Lehman.
